CoChat
Sign Up
Cited by 176Protein Kinase Regulation and GTPase SignalingCellular Mechanics and InteractionsHippo pathway signaling and YAP/TAZ

Rho-kinase: Regulation, (dys)function, and inhibition

Open access
Amin, Ehsan, Dubey, Badri Nath, Zhang, Si-Cai, Gremer, Lothar, Dvorsky, Radovan, Moll, Jens M., Taha, Mohamed S., Nagel-Steger, Luitgard +3 more·2013·bchm
DOI 10.1515/hsz-2013-0181PMC PMC5538733
Open this paper in CoChat — free account

Abstract

In a variety of normal and pathological cell types, Rho-kinases I and II (ROCKI/II) play a pivotal role in the organization of the nonmuscle and smooth muscle cytoskeleton and adhesion plaques as well as in the regulation of transcription factors. Thus, ROCKI/II activity regulates cellular contraction, motility, morphology, polarity, cell division, and gene expression. Emerging evidence suggests that dysregulation of the Rho-ROCK pathways at different stages is linked to cardiovascular, metabolic, and neurodegenerative diseases as well as cancer. This review focuses on the current status of understanding the multiple functions of Rho-ROCK signaling pathways and various modes of regulation of Rho-ROCK activity, thereby orchestrating a concerted functional response.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1515/hsz-2013-0181

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Effector proteins for RhoA fall primarily into two classes: scaffold proteins such as rhophilin, rhotekin, kinectin, and mDia, and serine/threonine protein kinases such as PKN, citron kinase, and ROCK.

    “The effector proteins for RhoA described so far fall primarily into two classes: scaffold proteins such as rhophilin, rhotekin, kinectin, and mammalian diaphanous-related formin (mDia) and serine/threonine protein kinases such as protein kinase N (PKN), citron kinase, and ROCK [116].”

    From RhoA Signaling in Neurodegenerative Diseases (2022) · cites this paper as [116]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 151

  1. Amano M Ito M Kimura K Fukata Y Chihara K Nakano T Matsuura Y Kaibuchi K 1996 Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase) J Biol Chem 271 20246 20249 8702756
  2. Amano M Chihara K Nakamura N Kaneko T Matsuura Y Kaibuchi K 1999 The COOH-terminus of Rho-kinase negatively regulates rho-kinase activity J Biol Chem 274 32418 32424 10542285
  3. Amano M Nakayama M Kaibuchi K 2010 Rho-kinase/ROCK: a key regulator of the cytoskeleton and cell polarity Cytoskeleton 67 545 554 20803696 PMC3038199
  4. Antoniu SA 2012 Targeting RhoA/ROCK pathway in pulmonary arterial hypertension Expert Opin Ther Targets 16 355 363 22449260
  5. Appels NM Bolijn MJ van Eijndhoven MA Stephens TC Beijnen JH Schellens JH 2011 Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor Cancer Chemother Pharmacol 67 137 145 20229082
  6. Baranwal S Alahari SK 2011 Rho GTPase effector functions in tumor cell invasion and metastasis Curr Drug Targets 12 1194 1201 21561416
  7. Begum N Sandu OA Ito M Lohmann SM Smolenski A 2002 Active Rho kinase (ROK-a) associates with insulin receptor substrate-1 and inhibits insulin signaling in vascular smooth muscle cells J Biol Chem 277 6214 6222 11739394
  8. Bishop AL Hall A 2000 Rho GTPases and their effector proteins Biochem J 348 241 255 10816416 PMC1221060
  9. Blum R Cox AD Kloog Y 2008 Inhibitors of chronically active ras: potential for treatment of human malignancies Recent Pat Anticancer Drug Discov 3 31 47 18289122
  10. Blumenstein L Ahmadian MR 2004 Models of the cooperative mechanism for Rho effector recognition: implications for RhoA-mediated effector activation J Biol Chem 279 53419 53426 15475352
  11. Brunsveld L Kuhlmann J Alexandrov K Wittinghofer A Goody RS Waldmann H 2006 Lipidated ras and rab peptides and proteins – synthesis, structure, and function Angew Chem 45 6622 6646 17031879
  12. Chen XQ Tan I Ng CH Hall C Lim L Leung T 2002 Characterization of RhoA-binding kinase ROKa implication of the pleckstrin homology domain in ROKa function using region-specific antibodies J Biol Chem 277 12680 12688 11815607
  13. Chiba Y Matsusue K Misawa M 2010 RhoA, a possible target for treatment of airway hyperresponsiveness in bronchial asthma J Pharmacol Sci 114 239 247 20948164
  14. Coleman ML Sahai EA Yeo M Bosch M Dewar A Olson MF 2001 Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I Nat Cell Biol 3 339 345 11283606
  15. Croft DR Olson MF 2006 The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms Mol Cell Biol 26 4612 4627 16738326 PMC1489131
  16. David M Petit D Bertoglio J 2012 Cell cycle regulation of Rho signaling pathways Cell Cycle 11 3003 3010 22825247 PMC3442911
  17. Davies SP Reddy H Caivano M Cohen P 2000 Specificity and mechanism of action of some commonly used protein kinase inhibitors Biochem J 351 95 105 10998351 PMC1221339
  18. Diviani D Soderling J Scott JD 2001 AKAP-Lbc anchors protein kinase A and nucleates Ga 12-selective Rho-mediated stress fiber formation J Biol Chem 276 44247 44257 11546812
  19. Doran JD Liu X Taslimi P Saadat A Fox T 2004 New insights into the structure-function relationships of Rho-associated kinase: a thermodynamic and hydrodynamic study of the dimer-to-monomer transition and its kinetic implications Biochem J 384 255 262 15291762 PMC1134108
  20. Dvorsky R Ahmadian MR 2004 Always look on the bright site of Rho: structural implications for a conserved intermolecular interface EMBO Rep 5 1130 1136 15577926 PMC1299188
  21. Dvorsky R Blumenstein L Vetter IR Ahmadian MR 2004 Structural insights into the interaction of ROCKI with the switch regions of RhoA J Biol Chem 279 7098 7104 14660612
  22. Ehrenschwender M Siegmund D Wicovsky A Kracht M Dittrich-Breiholz O Spindler V Waschke J Kalthoff H Trauzold A Wajant H 2010 Mutant PIK3CA licenses TRAIL and CD95L to induce non-apoptotic caspase-8-mediated ROCK activation Cell Death Differ 17 1435 1447 20379197
  23. Eto M Ohmori T Suzuki M Furuya K Morita F 1995 A novel protein phosphatase-1 inhibitory protein potentiated by protein kinase C. Isolation from porcine aorta media and characterization J Biochem (Tokyo) 118 1104 1107 8720121
  24. Eto M Barandier C Rathgeb L Kozai T Joch H Yang Z Luscher TF 2001 Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase Circ Res 89 583 590 11577023
  25. Faiz F Hooper AJ van Bockxmeer FM 2012 Molecular pathology of familial hypercholesterolemia, related dyslipidemias and therapies beyond the statins Crit Rev Clin Lab Sci 49 1 17 22214202
  26. Ferretti R Palumbo V Di Savino A Velasco S Sbroggio M Sportoletti P Micale L Turco E Silengo L Palumbo G 2010 Morgana/chp-1, a ROCK inhibitor involved in centrosome duplication and tumorigenesis Dev Cell 18 486 495 20230755
  27. Fried LF 2008 Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease Kidney Int 74 571 576 18528321
  28. Fukasawa K 2011 Aberrant activation of cell cycle regulators, centrosome amplification, and mitotic defects Horm Cancer 2 104 112 21761333 PMC10358062
  29. Furukawa N Ongusaha P Jahng WJ Araki K Choi CS Kim HJ Lee YH Kaibuchi K Kahn BB Masuzaki H 2005 Role of Rho-kinase in regulation of insulin action and glucose homeostasis Cell Metab 2 119 129 16098829
  30. Gelb MH Brunsveld L Hrycyna CA Michaelis S Tamanoi F Van Voorhis WC Waldmann H 2006 Therapeutic intervention based on protein prenylation and associated modifications Nat Chem Biol 2 518 528 16983387 PMC2892741
  31. Goto H Kosako H Tanabe K Yanagida M Sakurai M Amano M Kaibuchi K Inagaki M 1998 Phosphorylation of vimentin by Rho-associated kinase at a unique amino-terminal site that is specifically phosphorylated during cytokinesis J Biol Chem 273 11728 11736 9565595
  32. Hahmann C Schroeter T 2010 Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity Cell Mol Life Sci 67 171 177 19907920 PMC11115778
  33. Hanashiro K Brancaccio M Fukasawa K 2011 Activated ROCK II by-passes the requirement of the CDK2 activity for centrosome duplication and amplification Oncogene 30 2188 2197 21242972
  34. Heasman SJ Ridley AJ 2008 Mammalian Rho GTPases: new insights into their functions from in vivo studies Nat Rev Mol Cell Biol 9 690 701 18719708
  35. Hendrix A Maynard D Pauwels P Braems G Denys H Van den Broecke R Lambert J Van Belle S Cocquyt V Gespach C 2010 Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis J Natl Cancer Inst 102 866 880 20484105 PMC2886092
  36. Herbrand U Ahmadian MR 2006 p190-RhoGAP as an integral component of the Tiam1/Rac1-induced downregulation of Rho Biol Chem 387 311 317 16542153
  37. Hidalgo-Carcedo C Hooper S Chaudhry SI Williamson P Harrington K Leitinger B Sahai E 2011 Collective cell migration requires suppression of actomyosin at cell-cell contacts mediated by DDR1 and the cell polarity regulators Par3 and Par6 Nat Cell Biol 13 49 58 21170030 PMC3018349
  38. Iden S Collard JG 2008 Crosstalk between small GTPases and polarity proteins in cell polarization Nat Rev Mol Cell Biol 9 846 859 18946474
  39. Itzen A Goody RS 2011 Covalent coercion by Legionella pneumophila Cell Host Microbe 10 89 91 21843863
  40. Jaiswal M Gremer L Dvorsky R Haeusler LC Cirstea IC Uhlenbrock K Ahmadian MR 2011 Mechanistic insights into specificity, activity, and regulatory elements of the regulator of G-protein signaling (RGS)-containing Rho-specific guanine nucleotide exchange factors (GEFs) p115, PDZ-RhoGEF (PRG), and leukemia-associated RhoGEF (LARG) J Biol Chem 286 18202 18212 21454492 PMC3093892
  41. Jaiswal M Dvorsky R Ahmadian MR 2013a Deciphering the molecular and functional basis of Dbl family proteins: a novel systematic approach toward classification of selective activation of the Rho family proteins J Biol Chem 288 4486 4500 23255595 PMC3567697
  42. Jaiswal M Fansa EK Dvorsky R Ahmadian MR 2013b New insight into the molecular switch mechanism of human Rho family proteins: shifting a paradigm Biol Chem 394 89 95 23096567
  43. Jin S Exton JH 2000 Activation of RhoA by association of Ga(13) with Dbl Biochem Biophys Res Commun 277 718 721 11062019
  44. Joyce PL Cox AD 2003 Rac1 and Rac3 are targets for geranylgeranyltransferase I inhibitor-mediated inhibition of signaling, transformation, and membrane ruffling Cancer Res 63 7959 7967 14633727
  45. Karnoub AE Symons M Campbell SL Der CJ 2004 Molecular basis for Rho GTPase signaling specificity Breast Cancer Res Treat 84 61 71 14999155
  46. Khan OM Ibrahim MX Jonsson IM Karlsson C Liu M Sjogren AK Olofsson FJ Brisslert M Andersson S Ohlsson C 2011 Geranylgeranyltransferase type I (GGTase-I) deficiency hyperactivates macrophages and induces erosive arthritis in mice J Clin Invest 121 628 639 21266780 PMC3026725
  47. Khwaja A Sharpe CC Noor M Hendry BM 2006 The role of geranylgeranylated proteins in human mesangial cell proliferation Kidney Int 70 1296 1304 16929252
  48. Kimura K Ito M Amano M Chihara K Fukata Y Nakafuku M Yamamori B Feng J Nakano T Okawa K 1996 Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase) Science 273 245 248 8662509
  49. Kimura K Fukata Y Matsuoka Y Bennett V Matsuura Y Okawa K Iwamatsu A Kaibuchi K 1998 Regulation of the association of adducin with actin filaments by Rho-associated kinase (Rho-kinase) and myosin phosphatase J Biol Chem 273 5542 5548 9488679
  50. Klein RM Spofford LS Abel EV Ortiz A Aplin AE 2008 B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization Mol Biol Cell 19 498 508 18045987 PMC2230594
  51. Komers R 2011 Rho kinase inhibition in diabetic nephropathy Curr Opin Nephrol Hypertens 20 77 83 21076299
  52. Konstantinopoulos PA Karamouzis MV Papavassiliou AG 2007 Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets Nat Rev Drug Discov 6 541 555 17585331
  53. Koyama M Ito M Feng J Seko T Shiraki K Takase K Hartshorne DJ Nakano T 2000 Phosphorylation of CPI-17, an inhibitory phosphoprotein of smooth muscle myosin phosphatase, by Rho-kinase FEBS Lett 475 197 200 10869555
  54. Lane KT Beese LS 2006 Thematic review series: lipid posttranslational modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I J Lipid Res 47 681 699 16477080
  55. Larrea MD Hong F Wander SA da Silva TG Helfman D Lannigan D Smith JA Slingerland JM 2009 RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility Proc Natl Acad Sci USA 106 9268 9273 19470470 PMC2695095
  56. Lee DH Shi J Jeoung NH Kim MS Zabolotny JM Lee SW White MF Wei L Kim YB 2009 Targeted disruption of ROCK1 causes insulin resistance in vivo J Biol Chem 284 11776 11780 19276091 PMC2673246
  57. Li Z Dong X Wang Z Liu W Deng N Ding Y Tang L Hla T Zeng R Li L 2005 Regulation of PTEN by Rho small GTPases Nat Cell Biol 7 399 404 15793569
  58. Liao JK Seto M Noma K 2007 Rho kinase (ROCK) inhibitors J Cardiovasc Pharmacol 50 17 24 17666911 PMC2692906
  59. Ligeti E Welti S Scheffzek K 2012 Inhibition and termination of physiological responses by GTPase activating proteins Physiol Rev 92 237 272 22298657
  60. Litosch I 2011 RhoA co-ordinates with heterotrimeric G proteins to regulate efficacy Biochem Biophys Res Commun 415 215 219 22033406
  61. Loirand G Guerin P Pacaud P 2006 Rho kinases in cardiovascular physiology and pathophysiology Circ Res 98 322 334 16484628
  62. Lopez-Pedrera C Ruiz-Limon P Valverde-Estepa A Barbarroja N Rodriguez-Ariza A 2012 To cardiovascular disease and beyond: new therapeutic perspectives of statins in autoimmune diseases and cancer Curr Drug Targets 13 829 841 22250652
  63. Ma Z Kanai M Kawamura K Kaibuchi K Ye K Fukasawa K 2006 Interaction between ROCK II and nucleophosmin/B23 in the regulation of centrosome duplication Mol Cell Biol 26 9016 9034 17015463 PMC1636820
  64. Madigan JP Bodemann BO Brady DC Dewar BJ Keller PJ Leitges M Philips MR Ridley AJ Der CJ Cox AD 2009 Regulation of Rnd3 localization and function by protein kinase Ca-mediated phosphorylation Biochem J 424 153 161 19723022 PMC2868966
  65. Mardilovich K Olson MF Baugh M 2012 Targeting Rho GTPase signaling for cancer therapy Future Oncol 8 165 177 22335581
  66. Marrari Y Crouthamel M Irannejad R Wedegaertner PB 2007 Assembly and trafficking of heterotrimeric G proteins Biochemistry (Mosc) 46 7665 7677 PMC2527407 17559193
  67. Matsui T Maeda M Doi Y Yonemura S Amano M Kaibuchi K Tsukita S 1998 Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association J Cell Biol 140 647 657 9456324 PMC2140160
  68. Meiri D Greeve MA Brunet A Finan D Wells CD LaRose J Rottapel R 2009 Modulation of Rho guanine exchange factor Lfc activity by protein kinase A-mediated phosphorylation Mol Cell Biol 29 5963 5973 19667072 PMC2772734
  69. Mikelis CM Palmby TR Simaan M Li W Szabo R Lyons R Martin D Yagi H Fukuhara S Chikumi H 2013 PDZ-RhoGEF and LARG are essential for embryonic development and provide a link between thrombin and LPA receptors and Rho activation J Biol Chem 288 12232 12243 23467409 PMC3636907
  70. Miyamoto S Del Re DP Xiang SY Zhao X Florholmen G Brown JH 2010 Revisited and revised: is RhoA always a villain in cardiac pathophysiology? J Cardiovasc Transl Res 3 330 343 20559774 PMC3005405
  71. Momotani K Somlyo AV 2012 p63RhoGEF: a new switch for Gq-mediated activation of smooth muscle Trends Cardiovasc Med 22 122 127 22902181 PMC3472095
  72. Momotani K Artamonov MV Utepbergenov D Derewenda U Derewenda ZS Somlyo AV 2011 p63RhoGEF couples Ga(q/11)-mediated signaling to Ca2+ sensitization of vascular smooth muscle contractility Circ Res 109 993 1002 21885830 PMC3211138
  73. Morgan-Fisher M Wewer UM Yoneda A 2013 Regulation of ROCK activity in cancer J Histochem Cytochem 61 185 198 23204112 PMC3636696
  74. Mueller BK Mack H Teusch N 2005 Rho kinase, a promising drug target for neurological disorders Nat Rev Drug Discov 4 387 398 15864268
  75. Nakamura H Arakawa K Itakura H Kitabatake A Goto Y Toyota T Nakaya N Nishimoto S Muranaka M Yamamoto A 2006 Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial Lancet 368 1155 1163 17011942
  76. Narumiya S Tanji M Ishizaki T 2009 Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion Cancer Metastasis Rev 28 65 76 19160018
  77. Niault TS Baccarini M 2010 Targets of Raf in tumorigenesis Carcinogenesis 31 1165 1174 20047953
  78. Nimnual AS Taylor LJ Bar-Sagi D 2003 Redox-dependent downregulation of Rho by Rac Nat Cell Biol 5 236 241 12598902
  79. Noma K Kihara Y Higashi Y 2012 Striking crosstalk of ROCK signaling with endothelial function J Cardiol 60 1 6 22607993
  80. Nunes KP Rigsby CS Webb RC 2010 RhoA/Rho-kinase and vascular diseases: what is the link? Cell Mol Life Sci 67 3823 3836 20668910 PMC2996825
  81. Ohgushi M Sasai Y 2011 Lonely death dance of human pluripotent stem cells: ROCKing between metastable cell states Trends Cell Biol 21 274 282 21444207
  82. Oka M Fagan KA Jones PL McMurtry IF 2008 Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension Br J Pharmacol 155 444 454 18536743 PMC2579659
  83. Olson MF 2008 Applications for ROCK kinase inhibition Curr Opin Cell Biol 20 242 248 18282695 PMC2377343
  84. Park HJ Zhang Y Georgescu SP Johnson KL Kong D Galper JB 2006 Human umbilical vein endothelial cells and human dermal microvascular endothelial cells offer new insights into the relationship between lipid metabolism and angiogenesis Stem Cell Rev 2 93 102 17237547
  85. Raper A Kolansky DM Cuchel M 2012 Treatment of familial hypercholesterolemia: is there a need beyond statin therapy? Curr Atheroscler Rep 14 11 16 22135161
  86. Raptis L Arulanandam R Geletu M Turkson J 2011 The R(h)oads to Stat3: Stat3 activation by the Rho GTPases Exp Cell Res 317 1787 1795 21619876 PMC3129747
  87. Rath N Olson MF 2012 Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy EMBO Rep 13 900 908 22964758 PMC3463970
  88. Reddy R Chahoud G Mehta JL 2005 Modulation of cardiovascular remodeling with statins: fact or fiction? Curr Vasc Pharmacol 3 69 79 15638784
  89. Resh MD 2012 Targeting protein lipidation in disease Trends Mol Med 18 206 214 22342806 PMC3322242
  90. Richardson BT Dibble CF Borikova AL Johnson GL 2013 Cerebral cavernous malformation is a vascular disease associated with activated RhoA signaling Biol Chem 394 35 42 23096573 PMC3677706
  91. Riento K Ridley AJ 2003 Rocks: multifunctional kinases in cell behaviour Nat Rev Mol Cell Biol 4 446 456 12778124
  92. Riento K Guasch RM Garg R Jin B Ridley AJ 2003 RhoE binds to ROCK I and inhibits downstream signaling Mol Cell Biol 23 4219 4229 12773565 PMC156133
  93. Riganti C Aldieri E Doublier S Bosia A Ghigo D 2008 Statins-mediated inhibition of rho GTPases as a potential tool in anti-tumor therapy Mini Rev Med Chem 8 609 618 18537716
  94. Rikitake Y Liao JK 2005 Rho GTPases, statins, and nitric oxide Circ Res 97 1232 1235 16339495 PMC2633589
  95. Rikitake Y Kim HH Huang Z Seto M Yano K Asano T Moskowitz MA Liao JK 2005 Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection Stroke 36 2251 2257 16141422 PMC2633591
  96. Rizzino A 2010 Stimulating progress in regenerative medicine: improving the cloning and recovery of cryopreserved human pluripotent stem cells with ROCK inhibitors Regen Med 5 799 807 20868334 PMC3037821
  97. Roberts PJ Mitin N Keller PJ Chenette EJ Madigan JP Currin RO Cox AD Wilson O Kirschmeier P Der CJ 2008 Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification J Biol Chem 283 25150 25163 18614539 PMC2533093
  98. Roskoski R Jr 2003 Protein prenylation: a pivotal posttranslational process Biochem Biophys Res Commun 303 1 7 12646157
  99. Rossman KL Der CJ Sondek J 2005 GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors Nat Rev Mol Cell Biol 6 167 180 15688002
  100. Roy M Kung HJ Ghosh PM 2011 Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins Am J Cancer Res 1 542 561 21984972 PMC3186052
  101. Salminen A Suuronen T Kaarniranta K 2008 ROCK, PAK, and Toll of synapses in Alzheimer’s disease Biochem Biophys Res Commun 371 587 590 18466762
  102. Satoh K Fukumoto Y Shimokawa H 2011 Rho-kinase: important new therapeutic target in cardiovascular diseases Am J Physiol Heart Circ Physiol 301 H287 H296 21622831
  103. Sawada N Liao JK 2009 Targeting eNOS and beyond: emerging heterogeneity of the role of endothelial Rho proteins in stroke protection Expert Rev Neurother 9 1171 1186 19673606 PMC2929364
  104. Schmandke A Strittmatter SM 2007 ROCK and Rho: biochemistry and neuronal functions of Rho-associated protein kinases Neuroscientist 13 454 469 17901255 PMC2849133
  105. Schofield AV Bernard O 2013 Rho-associated coiled-coil kinase (ROCK) signaling and disease Crit Rev Biochem Mol Biol 48 301 316 23601011
  106. Sebti SM Hamilton AD 2000a Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues Expert Opin Invest Drugs 9 2767 2782 11093352
  107. Sebti SM Hamilton AD 2000b Inhibition of Rho GTPases using protein geranylgeranyltransferase I inhibitors Methods Enzymol 325 381 388 11036620
  108. Shi J Zhang L Wei L 2011 Rho-kinase in development and heart failure: insights from genetic models Pediatr Cardiol 32 297 304 21327630 PMC3085170
  109. Shimokawa H Rashid M 2007 Development of Rho-kinase inhibitors for cardiovascular medicine Trends Pharmacol Sci 28 296 302 17482681
  110. Somlyo AP 1997 Signal transduction. Rhomantic interludes raise blood pressure Nature 389 908 909 911 9353112
  111. Somlyo AP Somlyo AV 2000 Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II J Physiol 522 Pt 2 177 185 10639096 PMC2269761
  112. Somlyo AP Somlyo AV 2003 Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase Physiol Rev 83 1325 1358 14506307
  113. Somlyo AP Somlyo AV 2004 Signal transduction through the RhoA/Rho-kinase pathway in smooth muscle J Muscle Res Cell Motil 25 613 615 15750846
  114. Stenmark H 2009 Rab GTPases as coordinators of vesicle traffic Nat Rev Mol Cell Biol 10 513 525 19603039
  115. Street CA Bryan BA 2011 Rho kinase proteins – pleiotropic modulators of cell survival and apoptosis Anticancer Res 31 3645 3657 22110183 PMC3226732
  116. Sugimoto M Nakayama M Goto TM Amano M Komori K Kaibuchi K 2007 Rho-kinase phosphorylates eNOS at threonine 495 in endothelial cells Biochem Biophys Res Commun 361 462 467 17651694
  117. Suzuki Y Yamamoto M Wada H Ito M Nakano T Sasaki Y Narumiya S Shiku H Nishikawa M 1999 Agonist-induced regulation of myosin phosphatase activity in human platelets through activation of Rho-kinase Blood 93 3408 3417 10233893
  118. Takefuji M Kruger M Sivaraj KK Kaibuchi K Offermanns S Wettschureck N 2013 RhoGEF12 controls cardiac remodeling by integrating G protein- and integrin-dependent signaling cascades J Exp Med 210 665 673 23530122 PMC3620351
  119. Takeya R Taniguchi K Narumiya S Sumimoto H 2008 The mammalian formin FHOD1 is activated through phosphorylation by ROCK and mediates thrombin-induced stress fibre formation in endothelial cells EMBO J 27 618 628 18239683 PMC2262041
  120. Tan HB Zhong YS Cheng Y Shen X 2011 Rho/ROCK pathway and neural regeneration: a potential therapeutic target for central nervous system and optic nerve damage Int J Ophthalmol 4 652 657 22553739 PMC3340788
  121. Tang BL 2005 Alzheimer’s disease: channeling APP to non-amyloidogenic processing Biochem Biophys Res Commun 331 375 378 15850769
  122. Tesfamariam B 2006 The effects of HMG-CoA reductase inhibitors on endothelial function Am J Cardiovasc Drugs 6 115 120 16555864
  123. Tonges L Koch JC Bahr M Lingor P 2011 ROCKing regeneration: Rho kinase inhibition as molecular target for neurorestoration Front Mol Neurosci 4 39 22065949 PMC3207219
  124. Triola G Waldmann H Hedberg C 2012 Chemical biology of lipidated proteins ACS Chem Biol 7 87 99 22148864
  125. Tybulewicz VL Henderson RB 2009 Rho family GTPases and their regulators in lymphocytes Nat Rev Immunol 9 630 644 19696767 PMC4898593
  126. Uehata M Ishizaki T Satoh H Ono T Kawahara T Morishita T Tamakawa H Yamagami K Inui J Maekawa M 1997 Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension Nature 389 990 994 9353125
  127. Valderrama F Cordeiro JV Schleich S Frischknecht F Way M 2006 Vaccinia virus-induced cell motility requires F11L-mediated inhibition of RhoA signaling Science 311 377 381 16424340
  128. Vanni C Mancini P Ottaviano C Ognibene M Parodi A Merello E Russo C Varesio L Zheng Y Torrisi MR 2007 Ga13 regulation of proto-Dbl signaling Cell Cycle 6 2058 2070 17721084
  129. Walsh MP 2011 Vascular smooth muscle myosin light chain diphosphorylation: mechanism, function, and pathological implications IUBMB Life 63 987 1000 21990256
  130. Wang QM Liao JK 2012 ROCKs as immunomodulators of stroke Expert Opin Ther Targets 16 1013 1025 22925075 PMC3807092
  131. Wang Y Zheng XR Riddick N Bryden M Baur W Zhang X Surks HK 2009 ROCK isoform regulation of myosin phosphatase and contractility in vascular smooth muscle cells Circ Res 104 531 540 19131646 PMC2649695
  132. Ward Y Yap SF Ravichandran V Matsumura F Ito M Spinelli B Kelly K 2002 The GTP binding proteins Gem and Rad are negative regulators of the Rho-Rho kinase pathway J Cell Biol 157 291 302 11956230 PMC2199248
  133. Wen W Liu W Yan J Zhang M 2008 Structure basis and unconventional lipid membrane binding properties of the PH-C1 tandem of rho kinases J Biol Chem 283 26263 26273 18640982 PMC3258851
  134. Wettschureck N Offermanns S 2002 Rho/Rho-kinase mediated signaling in physiology and pathophysiology J Mol Med 80 629 638 12395147
  135. While A Keen L 2012 The effects of statins on mood: a review of the literature Eur J Cardiovasc Nurs 11 85 96 20875773
  136. Wiemer AJ Hohl RJ Wiemer DF 2009 The intermediate enzymes of isoprenoid metabolism as anticancer targets Anticancer Agents Med Chem 9 526 542 19519294
  137. Wiemer AJ Wiemer DF Hohl RJ 2011 Geranylgeranyl diphosphate synthase: an emerging therapeutic target Clin Pharmacol Ther 90 804 812 22048229
  138. Winter-Vann AM Casey PJ 2005 Post-prenylation-processing enzymes as new targets in oncogenesis Nat Rev Cancer 5 405 412 15864282
  139. Wirth A Benyo Z Lukasova M Leutgeb B Wettschureck N Gorbey S Orsy P Horvath B Maser-Gluth C Greiner E 2008 G12-G13-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension Nat Med 14 64 68 18084302
  140. Wittinghofer A Vetter IR 2011 Structure-function relationships of the G domain, a canonical switch motif Annu Rev Biochem 80 943 971 21675921
  141. Yasui Y Amano M Nagata K Inagaki N Nakamura H Saya H Kaibuchi K Inagaki M 1998 Roles of Rho-associated kinase in cytokinesis; mutations in Rho-associated kinase phosphorylation sites impair cytokinetic segregation of glial filaments J Cell Biol 143 1249 1258 9832553 PMC2133074
  142. Young SG Yang SH Davies BS Jung HJ Fong LG 2013 Targeting protein prenylation in progeria Sci Transl Med 5 171 173 PMC3725554 23390246
  143. Zhang H Sawashita J Fu X Korenaga T Yan J Mori M Higuchi K 2006 Transmissibility of mouse AApoAII amyloid fibrils: inactivation by physical and chemical methods FASEB J 20 1012 1014 16549653
  144. Zhao TT Le Francois BG Goss G Ding K Bradbury PA Dimitroulakos J 2010 Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins Oncogene 29 4682 4692 20562912
  145. Zhou H Li Y 2011 Long-term diabetic complications may be ameliorated by targeting Rho kinase Diabetes Metab Res Rev 27 318 330 21309060
  146. Zhou H Li YJ 2012 Rho kinase inhibitors: potential treatments for diabetes and diabetic complications Curr Pharm Des 18 2964 2973 22571664
  147. Zhou Q Liao JK 2009 Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy Curr Pharm Des 15 467 478 19199975 PMC2896785
  148. Zhou Q Liao JK 2010 Pleiotropic effects of statins. Basic research and clinical perspectives Circ J 74 818 826 20424337 PMC3807085
  149. Zhou Q Gensch C Liao JK 2011 Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease Trends Pharmacol Sci 32 167 173 21242007 PMC3080120
  150. Zieba BJ Artamonov MV Jin L Momotani K Ho R Franke AS Neppl RL Stevenson AS Khromov AS Chrzanowska-Wodnicka M 2011 The cAMP-responsive Rap1 guanine nucleotide exchange factor, Epac, induces smooth muscle relaxation by down-regulation of RhoA activity J Biol Chem 286 16681 16692 21454546 PMC3089510
  151. Zou W Teitelbaum SL 2010 Integrins, growth factors, and the osteoclast cytoskeleton Ann NY Acad Sci 1192 27 31 20392214

Cited by

Sorted by citations

Authors
Amin, E., Dubey, B. N., Zhang, S.-C., Gremer, L., Dvorsky, R., Moll, J. M., Taha, M. S., Nagel-Steger, L., Piekorz, R. P., Somlyo, A. V., & Ahmadian, M. R.
Affiliations
  • Heinrich Heine University Düsseldorf (DE)
  • Forschungszentrum Jülich (DE)
  • Institut für Biochemie und Molekularbiologie II, Medizinische Fakultät der Heinrich-Heine-Universität, D-40255 Düsseldorf, Germany
  • University of Virginia (US)
Corresponding author
Ahmadian, Mohammad R.
ORCID
Venue
bchm
Publisher
Walter de Gruyter GmbH
Published
2013-08-14
Volume
394
Issue
11
Pages
1399-1410
ISSN
  • 1431-6730 (ISSN-L)
  • 1437-4315
DOI
10.1515/hsz-2013-0181
PMC
PMC5538733
OpenAlex
W2066482548
Cited by
176
References
0
Citations by year
2026: 6 · 2025: 11 · 2024: 12 · 2023: 12 · 2022: 13 · 2021: 20 · 2020: 14 · 2019: 13 · 2018: 15 · 2017: 14 · 2016: 16 · 2015: 13 · 2014: 15 · 2013: 2
FWCI
5.78
Type
journal article
Language
en
Open access
Locations
  • Biological Chemistry (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • JuSER (Forschungszentrum Jülich) (submittedVersion, other-oa)
Funders
National Institute of General Medical Sciences (R01GM086457)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
Keywords
Rho kinase, ROCK1, ROCK2, Rho/ROCK signaling, cytoskeletal organization, smooth muscle, transcription factor regulation, cell contraction, cell motility, cell polarity, gene expression regulation, cardiovascular disease, metabolic disorders, neurodegenerative diseases, cancer, Rho kinase inhibition
MeSH terms
rhoC GTP-Binding Protein, Animals, Humans, Phosphorylation, Signal Transduction, Down-Regulation, Gene Expression Regulation, Enzymologic, Apoptosis, rho GTP-Binding Proteins, rhoA GTP-Binding Protein, rhoB GTP-Binding Protein, Cell Proliferation, Nitric Oxide Synthase Type III, rho-Associated Kinases, Protein Stability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review